Intellia Therapeutics Inc

Most Recent

  • Intellia scientist in lab working on CRISPR technology
    News

    CRISPR Stocks Are Soaring Amid Biotech Breakthrough

    By Rachel Curry
  • uploads///flasks _
    Company & Industry Overviews

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.

    By Daniel Collins
  • uploads///Intellia
    Company & Industry Overviews

    A Financial Overview of Intellia Therapeutics in September

    In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million.

    By Daniel Collins
  • uploads///virus _
    Company & Industry Overviews

    Analysts Are Mostly Positive on Intellia Therapeutics This Month

    On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24.

    By Daniel Collins
  • uploads///CRSP
    Company & Industry Overviews

    How CRISPR Therapeutics Is Positioned in September

    CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///molecule
    Company & Industry Overviews

    CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent

    On June 19, the co-owners of intellectual property associated with CRISPR-Cas9 genome editing technology were granted a US patent.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Why Editas Medicine Fell 7.8% on Monday

    On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Intellia Therapeutics Stock Fell 9.8% on Monday

    On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.

    By Mike Benson
  • uploads///puzzle _
    Company & Industry Overviews

    Crispr Therapeutics Stock Fell 12.6% on June 11

    On June 11, Crispr Therapeutics (CRSP) stock fell 12.6% to $59.57 over concerns that the CRISPR-CAS9 Gene Therapy causes cancer.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.